Evonetix is revolutionizing gene synthesis with the aim of producing DNA at scale to enable many applications in the rapidly growing field of synthetic biology, across a wide range of industries, from pharmaceuticals to industrial biotech, specialty chemicals, renewables, bioremediation, agriculture and potentially also digital data storage. The company’s platform is based upon a novel silicon array and unique synergistic thermal control chemistry, capable of synthesizing oligonucleotides in parallel, at each of the 10,000 miniaturized reaction sites.




Colin McCracken, CEO

Matthew Hayes, CTO

Raquel Sanches-Kuiper, VP of Technology